People: Avantogen Oncology Inc (AVTO.PK)

AVTO.PK on OTC Markets Group

0.00USD
8 Feb 2013
Price Change (% chg)

$-0.00 (-44.44%)
Prev Close
$0.01
Open
$0.00
Day's High
$0.00
Day's Low
$0.00
Volume
20,500
Avg. Vol
674
52-wk High
$0.02
52-wk Low
$0.00

Search Stocks

Summary

Name Age Since Current Position

William Ardrey

 41 Chairman of the Board, Chief Executive Officer

Michael Hillmeyer

 44 2007 Chief Financial Officer, Director

Lee Cole

 48 2006 Director
» Insider Trading

Biographies

Name Description

William Ardrey

 Dr. Ardrey is Chairman of the Board, Chief Executive Officer of Avantogen Oncology, Inc. Dr. William Ardrey commenced his career as a Manager in the international trading field at Trade Management International, then became an analyst and subsequently President of Fiduciary Communications Group, where he started and headed the financial information, financial publishing and broker dealer operations. Following the sale of the business to Thomson Financial Group, Dr. Ardrey became a President at Thomson. Since the sale to Thomson, Dr. Ardrey has served as President of CustomVis, Chief Executive Officer of Regenera Ltd. and President of a large eye hospital group in Australia. Dr. Ardrey is Chairman of the Board of Directors of Avantogen Limited and a director of Opto Global and Nova Aerospace.

Michael Hillmeyer

 Michael Hillmeyer has been appointed as Chief Financial Officer of Avantogen Oncology, Inc. He was appointed as the Director of the Company on January 24, 2007. Michael Hillmeyer is the founder and managing director of Atina Group International Ltd., an advisory boutique that focuses on providing strategic, financial and operational advice to firms in the health care and information technology industries. In 2004 and 2005, Mr. Hillmeyer was corporate strategist for Regenera Ltd., a listed biotech firm in Australia. Prior thereto, he was an equity research analyst in the Corporate Strategy and Research division of Merrill Lynch in New York and Boston for over five years, where his final title was Vice President. Prior to his graduate studies in business and international affairs at Columbia University, Mr. Hillmeyer worked in the information technology industry. .

Lee Cole

 Lee J. Cole is director of Avantogen Oncology, Inc. Lee J. Cole is the Chairman of Gardant Pharmaceuticals, Inc. and has served in that position since September 2004. He is also currently the interim Chief Executive Officer of Electronic Game Card, Inc. Since 1998, Mr. Cole has been a principal with Tech Capital Group, a technology consulting and investment firm that has investments in private and public information and healthcare technology companies. Mr. Cole is a director of Enhance Biotech, Inc., NeuroBioscience, Inc., Electronic Game Card, Inc. and Advance Nanotech, Inc.

Basic Compensation

Name Fiscal Year Total

William Ardrey

 --

Michael Hillmeyer

 --

Lee Cole

 --
As Of 

Options Compensation

Name Options Value

William Ardrey

 0 0

Michael Hillmeyer

 0 0

Lee Cole

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks